Affiliations: [a] Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt | [b] Clinical Hematology Unit, Internal Medicine Department, Assiut University, Assiut, Egypt | [c] Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt | [d] Clinical Oncology Department, Assiut University, Assiut, Egypt | [e] Department of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt | [f] Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt
Correspondence:
[*]
Corresponding author: Helal F. Hetta, Department of Medical Microbiology and Immunology Faculty of Medicine, Assiut University, Assiut, Egypt Tel.: +2 01002386255; ORCID iD: 000-0001-8541-7304 E-mail: helalhetta@aun.edu.eg;helalhetta@yahoo.com.
Abstract: BACKGROUND: The bone marrow immunosuppressive microenvironment of AML patients sustains and modulates proliferation, survival and drug resistance of AML through deregulation of both innate and adaptive immune response. We aimed to investigate the level of Tregs, expression of Tim-3 on peripheral blood T cells, expression of CD200 in myeloid blasts in newly diagnosed AML patients with normal cytogenetics (AML-NC) and their prognostic impact. PATIENTS AND METHODS: This study included 40 patients with de novo AML-NC and 20 healthy controls. Flow-cytometry was used for detection of CD4+CD25+high FoxP3+ regulatory T cells, Tim-3 expression on peripheral blood T cells and CD200 expression on myeloid blasts. RESULTS: The percentages of CD4+CD25+high and CD4+CD25+high Foxp3+ Tregs were significantly increased in AML patients than controls. The levels of Tregs, Tim-3/CD4+, Tim-3/CD8+, CD200 and MFI of CD200 were significantly lower in responding patients than in those with persistent leukemia. Only high CD200 expression (> 50%) showed statistically significant worse OS with P< 0.04. CONCLUSION: The increased levels of Tregs, Tim-3 expression on peripheral blood T cells and CD200 expression in myeloid blast in AML patients could play a role in the development of AML. Analysis of these markers could serve as prognostic markers and might guide the therapy in AML patients in the future.
Keywords: Regulatory T cells, CD200, TIM3, acute myeloid leukemia, normal cytogenetics
